Brief: Altamira Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
29/12/2023 13:49
Dec 29 (Reuters) - Altamira Therapeutics Ltd CYTO.O :
* ALTAMIRA THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ
MINIMUM BID
PRICE REQUIREMENT
Source text for Eikon: ID:nGNXfVWrN
Further company coverage: CYTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Altamira Therapeutics
See all newsBrief: Altamira Therapeutics Reports Full Year 2024 Results
Brief: Altamira Therapeutics Announces Transition From Nasdaq To OTC Markets
Brief: Altamira Therapeutics Provides Update On Nasdaq Listing
Brief: Altamira Therapeutics Provides Business Update And First Half 2024 Financial Results
Brief: Altamira Therapeutics Announces Pricing Of Up To $12.0 Mln Public Offering